ArticleDrug delivery and translational research2026
Evaluation of nanoencapsulated bevacizumab combined with paclitaxel in a colorectal cancer xenograft model.
Article in Drug delivery and translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Nanomedicine-Based Therapeutic Approaches in Colorectal Cancer Using Patient-Derived Xenograft Models: Prospects and Challenges.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The combination of bevacizumab and paclitaxel (PTX) has exhibited synergistic antitumor effects in different types of solid cancer tumors probably due to a potential increase of intratumoral PTX facilitated by the action of the antiangiogenic agent bevacizumab. The aim of this study was to evaluate the benefits of using nanoencapsulated bevacizumab (B-NP-DEX) in combination with paclitaxel as part of a systemic therapeutic regimen for colorectal cancer (CRC). For this purpose, bevacizumab (either as aqueous solution or nanoencapsulated in albumin based-nanoparticles coated with dextran) in combination with paclitaxel were intravenously administered and evaluated in a xenograft mouse model of CRC. Both treatments (free and nanoencapsulated bevacizumab and PTX) significantly reduced tumor growth, metabolic activity, and weight, extending tumor-doubling time by approximately 5 days when compared with control animals (receiving saline). However, animals treated with the combination between PTX and B-NP-DEX showed enhanced antitumor effects than the conventional treatment with free bevacizumab, including a greater reduction in tumor growth rate, VEGF levels, and proliferation markers. PET imaging and biodistribution analysis revealed an 8-fold higher tumor-to-plasma ratio for the nanoencapsulated bevacizumab, suggesting improved tumor targeting via the enhanced permeability and retention effect. These findings support the potential of nanoparticle-based delivery systems to increase therapeutic efficacy while potentially reducing systemic toxicity, warranting further investigation into their role in optimizing antiangiogenic chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.